Prostacyclin treatment successfully delays the need for lung transplantation in many patients with progressive primary pulmonary hypertension by vasodilating pulmonary arteries. However, the treatment of pulmonary hypertension with prostacyclin may cause a paradoxical increase in pulmonary artery pressure, as shown in this case.
Get full access to this article
View all access options for this article.
References
1.
Rubin LJ: Primary pulmonary hypertension. N Engl J Med336:111-117, 1997.
D’Alonzo GE, Barst RJ, Ayres SM, et al: Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med115:343-349, 1991.
4.
Barst RJ, Rubin LJ, Long WA, et al: Epoprostenol therapy for primary pulmonary hypertension: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med334:296-302, 1996.
5.
Abenhaim L, Moride Y, Brenot F, et al: Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med335:609-616, 1996.
6.
Nall KC, Rubin LJ, Lipskind S, et al: Reversible pulmonary hypertension associated with anorexigen use. Am J Med91:97-99, 1991.
7.
Rich S, Kaufmann E, Levy PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med327:76-81, 1992.
8.
Long W, Rubin L, Barst RJ, et al: Randomized trial of conventional therapy alone vs conventional therapy plus continuous infusion of prostacyclin in primary pulmonary hypertension. Am Rev Respir Dis149:A538, 1993.
9.
Higgenbottani TW, Spiegelhalter D, Scott JP, et al: The value of prostacyclin (epoprostenol) and heart-lung transplantation for severe pulmonary hypertension. Br Heart J70:36640, 1993.
